586374-72-3 Usage
Molecular structure
The compound has a pyridinone core and a substituted phenylmethyl group.
Bromine atom
A halogen atom attached to the pyridinone ring.
Difluorophenylmethoxy group
A fluorinated aromatic ring attached to the phenylmethyl group through a methoxy group.
Methyl group
A simple alkyl group attached to the pyridinone ring.
Aminomethyl group
A functional group consisting of an amino group attached to a methyl group.
Pharmaceutical research
The compound is an important intermediate in pharmaceutical research and synthesis.
Medicinal drug development
The compound has potential applications in the development of medicinal drugs due to its diverse chemical structure.
Industrial applications
The compound may have other industrial uses beyond pharmaceuticals.
Hazardous properties
The compound should be handled with caution and used responsibly due to its complexity and potentially hazardous properties.
Check Digit Verification of cas no
The CAS Registry Mumber 586374-72-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,8,6,3,7 and 4 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 586374-72:
(8*5)+(7*8)+(6*6)+(5*3)+(4*7)+(3*4)+(2*7)+(1*2)=203
203 % 10 = 3
So 586374-72-3 is a valid CAS Registry Number.
586374-72-3Relevant academic research and scientific papers
Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase
Selness, Shaun R.,Devraj, Rajesh V.,Monahan, Joseph B.,Boehm, Terri L.,Walker, John K.,Devadas, Balekudru,Durley, Richard C.,Kurumbail, Ravi,Shieh, Huey,Xing, Li,Hepperle, Michael,Rucker, Paul V.,Jerome, Kevin D.,Benson, Alan G.,Marrufo, Laura D.,Madsen, Heather M.,Hitchcock, Jeff,Owen, Tom J.,Christie, Lance,Promo, Michele A.,Hickory, Brian S.,Alvira, Edgardo,Naing, Win,Blevis-Bal, Radhika
body text, p. 5851 - 5856 (2010/07/05)
The identification and evolution of a series of potent and selective p38 inhibitors is described. p38 inhibitors based on a N-benzyl pyridinone high-throughput screening hit were prepared and their SAR explored. Their design was guided by ligand bound co-
SUBSTITUTED PYRIDINONES
-
Page/Page column 333-334, (2008/06/13)
Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.
